Search

everythinglearnresearchcommunity

for

Search:↓

The user is using finasteride and minoxidil for hair loss but feels progress is slow and is considering switching to dutasteride after 12 months. They notice minor shedding but are unsure if the medication is stabilizing their hair loss.

User shared 4-month progress on hair loss treatment using 0.25mg finasteride daily and topical minoxidil daily, noting cognitive decline possibly linked to finasteride. Users discussed side effects, alternative treatments, and shared similar experiences.

Fluridil and pyrilutamide are equally effective in stabilizing hair loss, with no regrowth observed. The user also uses dutasteride and minoxidil in their treatment.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

A 31-year-old male switched from finasteride to oral dutasteride (0.5mg, 2x a week) and uses liquid minoxidil daily for hair loss. He experienced shedding and regrowth but is considering increasing dutasteride to 3x a week due to concerns about hair density and ongoing issues.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.

Piroctone olamine is more effective than ketoconazole for increasing hair growth and reducing itching and dandruff. Treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

User considers adding Alfatradiol to their topical finasteride treatment for hair loss. Others discuss Alfatradiol as a weak estrogen and 5α-reductase inhibitor used for pattern hair loss in men and women.

A user beginning to take Pyrilutamide as a treatment for their hair loss, and other users sharing their experiences with the drug or similar treatments such as Minoxidil, Finasteride, and RU58841.

User on fin, minox, and ketoconazole seeks to add another topical anti-androgen. Hierarchy of effectiveness: 1. RU55841, 2. Fluridil - Eucapil, 3. CB-03-01 - Breezula, 4. Ketoconazole; alfatradiol suggested as addition.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

Dutasteride may cause mental fog, vision blurriness, and sleep issues. Users suggest trying topical versions of the drug to mitigate side effects.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The conversation discusses increasing dutasteride dosage to 2.5mg for hair loss treatment, with suggestions to take multiple 0.5mg pills due to the unavailability of 2.5mg tablets in the US. Users also mention using ketoconazole and express skepticism about the effectiveness and safety of high doses.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

. This conversation is a satire post about a user who appears to have an abundance of hair, with other users commenting and asking questions about the treatments they use for their hair loss. Treatments discussed include minoxidil and finasteride.

The user experienced initial success with topical finasteride 0.025% and melatonin but noticed rapid hair thinning after three months. They are considering switching to a higher dose of topical finasteride or oral finasteride, as advised by others, while being cautious about potential side effects.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

Using a low dose of topical Tamoxifen effectively reduces gynecomastia caused by finasteride, with minimal side effects. The solution involves mixing Tamoxifen with ethanol and propylene glycol, applied daily to the chest.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

The conversation discusses the effectiveness and systemic absorption of Topilutamide/Fluridil/Eucapil and topical Dutasteride for hair loss. Users are sharing their experiences and seeking success stories with these treatments.

The user switched from Finasteride to topical Dutasteride, Pyrilutamide, and Minoxidil due to hair loss, then decided to switch to oral Dutasteride because of pregnancy concerns. They are considering the frequency of oral Dutasteride use, with suggestions of using it a few times a week for better results and fewer side effects.

The user started using topical minoxidil 5% and ketoconazole shampoo for hair loss, noticing minimal progress after three months, with fine hairs appearing. They experienced a setback when reducing the application to once a day but resumed twice daily applications.

Switching from Arimidex to Raloxifene worsened hair loss despite using Dutasteride. The user added oral Minoxidil, dermastamping, and RU58841 to their regimen to address the issue.

Zinc picolinate and saw palmetto may lower DHT but are less effective than finasteride. Finasteride and minoxidil are preferred treatments, with ketoconazole shampoo as a suggested addition.

A 24-year-old with mild temple recession is using 5% minoxidil without noticeable effects and has started topical finasteride but is anxious about potential side effects. They are considering a specialist visit for peace of mind despite the cost.